DeepQure

What DeepQure does

DeepQure Inc. is a Seoul, South Korea-based clinical-stage medical device company developing HyperQure, the world's first laparoscopic extravascular renal denervation (RDN) system for the treatment of resistant hypertension. The company's core technology delivers temperature-controlled radiofrequency (RF) energy from outside the renal artery using a segmented electrode tip that wraps circumferentially around the vessel, enabling complete 360-degree denervation regardless of nerve distribution. Three electrode sizes address renal arteries ranging from 2mm to 11mm in diameter, covering branched and accessory arteries that catheter-based intravascular RDN systems cannot reach. The system is compatible with both laparoscopic and robotic (da Vinci SP single-port) surgical platforms and comprises a generator base unit, a shaft and electrode assembly, and a surgeon-controlled handle with safety features including an emergency release system.

The company originated from government-funded research initiated by co-founder Dr. Chang-Wook Jeong at Seoul National University Hospital and was incorporated as DeepQure Inc. DeepQure is currently conducting first-in-human trials in Korea (10 patients enrolled, completed December 2025) and an Early Feasibility Study across six leading US academic medical centers (Stanford, Mayo Clinic, Emory, UC Irvine, University of Florida, Henry Ford Health), with IRB approvals secured. The company has filed 170+ patents across more than 10 countries, received MFDS Breakthrough Device Designation (Innovative Medical Device No. 36, July 2023), and FDA Investigational Device Exemption approval (June 2024). The pipeline extends beyond hypertension to atrial fibrillation (MFDS cleared July 2025) and other sympathetic-mediated cardiovascular indications.

DeepQure's business model is anchored on direct enterprise sales of the HyperQure Class III medical device to hospital systems following FDA Pre-Market Approval and Korean MFDS clearance, with pricing benchmarked against industry RDN procedural costs of US$5,000-$10,000 per procedure. The company is also pursuing strategic collaboration with global medtech partners for potential co-development or market development. To date, DeepQure has raised approximately $18 million in total venture funding, most recently via a Series C round (April 2025) led by Sui Generis Partners (수이제네리스 파트너스). The company operates with a leadership team combining clinical innovators (CMO Dr. Jeong), finance executives (Chairman Chan-Ho Park, ex-Goldman Sachs/Warburg Pincus), and regulatory specialists (Global VP Jason G. Jones, ex-SoniVie), and has not yet generated commercial revenue.

Name

DeepQure

Legal name

DeepQure Inc.

Website

https://www.deepqure.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

DeepQure is a clinical-stage Korean medical device company developing HyperQure, the world's first laparoscopic extravascular renal denervation system for treating resistant hypertension, with an expanding pipeline into atrial fibrillation.

Ownership category

akta.pro rank

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Medical Device Hardware Sales: DeepQure is a clinical-stage medtech company developing and preparing to commercialize the HyperQure extravascular RDN system. As a Class III medical device targeting hospital-based interventional procedures, revenue will be generated through direct device sales to hospital systems following regulatory approval (FDA PMA / Korean MFDS). The company is also exploring strategic partnerships with global medtech firms.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

DeepQure is developing and preparing to commercialize the HyperQure system, the world's first laparoscopic extravascular renal denervation (RDN) device. It performs 360-degree circumferential RF ablation of renal nerves from outside the renal artery for treating resistant hypertension. The system consists of a Generator (RF energy source), Shaft and Electrode (surgical instrument with three electrode sizes for 2-11mm arteries), and Handle (surgeon control with safety features), and is compatible with laparoscopic and single-port robotic surgery.

Product overview

DeepQure offers HyperQure, the world's first laparoscopic extravascular renal denervation (RDN) system. The core HyperQure RDN System consists of three integrated components: a Generator (RF energy source), Shaft and Electrode (surgical instrument), and Handle (surgeon control interface). The system performs 360° circumferential nerve ablation from outside the renal artery using temperature-controlled RF ablation. A variant, HyperQure RDM System, is being developed for atrial fibrillation treatment. All products are currently in clinical trial stage.

Differentiator

Problem solved

Functional benefit

Brands

• HyperQure: The world's first laparoscopic extravascular renal denervation (RDN) system designed for 360° circumferential ablation of renal nerves from outside the vessel. HyperQure is a next-generation RDN device targeting resistant hypertension and atrial fibrillation.

Products and services

• HyperQure RDN System World's first laparoscopic extravascular renal denervation system that delivers radiofrequency energy from outside the renal artery for complete 360-degree circumferential nerve ablation. Consists of Generator (RF energy source and control unit), Shaft and Electrode (surgical instrument that wraps around the renal artery to deliver RF energy), and Handle (surgeon control interface with safety features). Designed for treating resistant hypertension in hospital-based interventional settings, with three electrode sizes covering renal arteries from 2mm to 11mm in diameter.
• HyperQure RDM System Laparoscopic renal denervation system variant under development for atrial fibrillation treatment. Uses the same extravascular RDN approach as the core HyperQure system but targets cardiac arrhythmia applications in patients with recurrent AF following pulmonary vein isolation (PVI) and resistant hypertension.

Quantifiable outcome

• 51 mmHg average reduction in systolic blood pressure at 12 months in Korean first-in-human study (baseline 165 mmHg to 114 mmHg)
• +7 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Stanford UniversitycoreStrategic or Co-development PartnerStanford University is one of six leading US academic medical centers conducting DeepQure's IDE Early Feasibility Study for the HyperQure extravascular RDN system. Stanford is participating alongside Mayo Clinic, UC Irvine, University of Florida, Henry Ford Health System, and Emory University.
• Mayo CliniccoreStrategic or Co-development PartnerMayo Clinic is one of six leading US academic medical centers conducting DeepQure's IDE Early Feasibility Study for HyperQure. Mayo Clinic is among the first institutions to receive IRB approval for the US clinical program.
• UC Irvine (University of California, Irvine)coreStrategic or Co-development PartnerUC Irvine was the site of the first US clinical procedure with the HyperQure device (January 17, 2025), performed by Professor Pengbo Jiang. UC Irvine was among the first institutions to grant IRB approval for DeepQure's US IDE clinical trial.
• University of FloridacoreStrategic or Co-development PartnerUniversity of Florida is one of six leading US academic medical centers participating in DeepQure's IDE Early Feasibility Study for the HyperQure extravascular RDN system.
• Henry Ford Health SystemcoreStrategic or Co-development PartnerHenry Ford Health System is one of six US academic medical centers participating in DeepQure's US IDE Early Feasibility Study. Dr. Herbert Aronow, Medical Director of Heart & Vascular Service Line at Henry Ford Health, serves as a DeepQure advisor.
• Emory University Medical CentercoreStrategic or Co-development PartnerEmory University Medical Center is one of the US academic medical centers conducting DeepQure's US IDE Early Feasibility Study for the HyperQure extravascular RDN system.
• University of ArizonacoreStrategic or Co-development PartnerUniversity of Arizona is one of the seven US university hospitals planned for DeepQure's US clinical trial program for HyperQure, per the December 2024 announcement.
• CBSET (Center for Biomedical Science and Engineering Technology)coreStrategic or Co-development PartnerCBSET is a GLP-certified preclinical research facility that conducted large-animal (porcine) studies for DeepQure's FDA submission. Dr. Abraham Rami Tzafriri of CBSET presented 12-week safety and efficacy data for HyperQure at TCT 2024. CBSET's preclinical work supported FDA IDE approval for the HyperQure system.
• Multiple Global Medtech Companies (unnamed)minorStrategic or Co-development PartnerDeepQure has received strong interest from multiple major medtech firms and is in active discussions regarding strategic collaboration with one global medtech player for partnership and/or market development.
• Seoul National University HospitalcoreStrategic or Co-development PartnerDeepQure's Korean first-in-human clinical trial is conducted at Seoul National University Hospital (SNUH) and additional Korean institutions. Professor Chang-Wook Jeong, co-founder and CMO of DeepQure, is Professor of Urology at SNUH and led the research program that developed the HyperQure technology.

Scale indicators7 records

Recent moves6 records

Expansion highlights7 records

Others

• Intuitive Surgical: Intuitive Surgical manufactures the da Vinci SP single-port robotic platform used to deploy HyperQure. Technology/integration partner rather than competitor; strategic relationship already demonstrated at UC Irvine.

Broad incumbents

• Boston Scientific: Boston Scientific acquired SoniVie for $540M (March 2025) and is a likely acquirer of or strategic partner for DeepQure given its cardiovascular interventional portfolio and stated interest in RDN.
• Otsuka Holdings: Otsuka acquired Recor Medical (~$800M, 2023) and is commercializing the Paradise RDN system globally. Diversified pharma-medtech incumbent with deep cardiovascular and renal portfolios; potential strategic partner for DeepQure.

Emerging players

• Cala Health: Cala Health develops non-invasive wearable neuromodulation therapies (TAPS therapy) for hypertension and tremor. Adjacent emerging player pursuing device-based hypertension treatment via a different mechanism.
• Kona Medical: Kona Medical is pursuing non-invasive externally-delivered ultrasound RDN for hypertension. Earlier-stage competitor with a different delivery mechanism but overlapping target indication.
• Mercator MedSystems: Mercator is developing catheter-based micro-infusion RDN (Bullfrog system) for hypertension. Earlier-stage competitor with overlapping indication but different delivery modality.
• Ablative Solutions: Ablative Solutions is developing a percutaneous chemical RDN approach (Peregrine System) for resistant hypertension. Smaller, earlier-stage competitor focused on a different energy modality but the same hypertension indication.

Direct peers

• SoniVie (Boston Scientific): SoniVie developed an intravascular ultrasound RDN system and was acquired by Boston Scientific for $540M in March 2025. Closest extravascular-adjacent competitor and a key valuation/acquisition comparable for DeepQure.
• Medtronic: Medtronic markets Symplicity Spyral, the leading FDA-approved catheter-based renal denervation system. Direct competitor to DeepQure in treating resistant hypertension via RDN; DeepQure's clinical differentiation is benchmarked against Symplicity Spyral's ~5.4 mmHg BP reduction.
• Recor Medical (Otsuka): Recor's Paradise ultrasound RDN system is FDA-approved for hypertension and competes head-to-head with DeepQure's HyperQure. Acquired by Otsuka in 2023 (~$800M); directly comparable efficacy benchmark (Paradise shows ~8.5 mmHg reduction).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/deepqure-inc

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DeepQure